<?xml version="1.0" encoding="UTF-8"?>
<p>A controlled trial enrolled 120 chronic HCV carriers into two groups: IFN-Î± alone or a combination of IFN and CsA. The combination group significantly increased the sustained virological response rate with similar safety profiles in the two groups. The benefit was especially marked in patients with HCV genotype 1 and high viral loads.
 <sup>
  <xref rid="bibr60-1759720X20947296" ref-type="bibr">60</xref>
 </sup>
</p>
